EFFECTS OF INSPIRATORY MUSCLE TRAINING ON DYSPNEA AND PULMONARY FUNCTION TEST IN ASTHMATIC PATIENTS
DOI:
https://doi.org/10.71000/xtvvqm52Keywords:
Asthma, Inspiratory Muscle Training, Dyspnea, Pulmonary Function, Rehabilitation, TelerehabilitationAbstract
Background: Asthma is a chronic respiratory condition characterized by airway inflammation and hyperresponsiveness, often leading to dyspnea and impaired pulmonary function. Despite pharmacological advancements, many patients continue to experience symptoms that impact their daily lives. Inspiratory Muscle Training (IMT) has emerged as a non-pharmacological intervention aimed at strengthening inspiratory muscles, reducing respiratory effort, and improving breathing efficiency.
Objective: This review examines the effects of IMT on dyspnea and pulmonary function in asthmatic patients, synthesizing recent research findings to evaluate its potential as a complementary therapy.
Methods: A narrative review of the latest studies was conducted, focusing on IMT’s impact on dyspnea perception, inspiratory muscle strength, pulmonary function parameters (FEV1, FVC, PEFR), and its integration into modern rehabilitation strategies.
Results: IMT consistently reduces dyspnea, enhances maximal inspiratory pressure (MIP), and improves exercise tolerance. However, its effects on FEV1 and FVC remain inconclusive, highlighting the need for standardized training protocols. The emergence of telerehabilitation-based IMT shows promise in making respiratory training more accessible.
Conclusion: IMT is a safe, effective adjunct therapy for asthma management, offering non-invasive symptom relief. Future research should standardize protocols, explore digital health applications, and investigate long-term effects to optimize its integration into clinical practice.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mariam Javaid , Muhammad Naveed Babur, Saleh Shah, Umera Iftikhar, Rimsha Khalid , Mariam Mohsin (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.